NYSE · Healthcare · Diagnostics & Research · USA
Quest Diagnostics Inc is a large cap company (market value between $10 billion and $200 billion) in the Diagnostics & Research industry.
Quest Diagnostics provides diagnostic laboratory testing services and insights across the United States healthcare system, serving physicians, hospitals, patients, and other healthcare organizations. The company operates patient service centers and reference laboratories, offering routine and advanced diagnostic testing in areas including oncology, molecular diagnostics, and genetic testing.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Quest Diagnostics Inc stock.
Slightly overvalued: intrinsic value $223.10 per share, market price $234.91, margin of safety -5.3% (as of 2026-10-19).
Discounting its cash flows at 7.9% (average of 3 methods) values the shares at $223.10; the price of $234.91 is 5% above that value, and 80% of that value comes from beyond year five.
Leak Score: 53/100 on 12 of 12 signals (Weak Signal).
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
DGX is slightly overvalued (as of the 2026-10-19 close). Discounting its cash flows at 7.9% (average of 3 methods) values the shares at $223.10; the price of $234.91 is 5% above that value, and 80% of that value comes from beyond year five.
$223.10 per share (as of the 2026-10-19 close), against a market price of $234.91. That is a margin of safety of -5.3%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
53 out of 100, which we rate "Weak Signal", on 12 of 12 value investing signals.